BACKGROUND. The therapeutic options for patients with polymyositis or dermatomyositis that is resistant to corticosteroids are limited, unproved, and often toxic. Uncontrolled trials concluded that both plasma exchange and leukapheresis are beneficial, but despite the considerable use of these approaches, proof of their efficacy is lacking. METHODS. Thirty-nine patients with definite polymyositis or dermatomyositis were randomly assigned to receive plasma exchange (replacement of one volume of plasma with 5 percent albumin in saline), leukapheresis (removal of 5 x 10(9) to 10 x 10(9) lymphocytes), or sham apheresis in a double-blind manner, with 12 treatments given over a one-month period. Muscle strength, functional capacity, and serum levels of muscle-associated enzymes were measured before and after the 12 procedures. RESULTS. In each group 3 of 13 patients had improvements in strength and functional capacity. The condition of 3 patients treated with leukapheresis and 1 treated with plasma exchange deteriorated, and it was unchanged in the other 26 patients. Adverse effects of apheresis included the need for a central venous catheter (9 patients), major vasovagal episodes (3 patients), and severe citrate reactions (2 patients). Despite the occurrence of significant reductions in the serum levels of muscle enzymes with plasma exchange (P less than 0.001) and significant decreases in lymphocyte counts with leukapheresis (P = 0.002), there were no significant differences among the three treatment groups in the final muscle strength or functional capacity of the patients. CONCLUSIONS. As treatments for corticosteroid-resistant polymyositis or dermatomyositis, leukapheresis and plasma exchange are no more effective than sham apheresis.
Source Information
National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20892.
This article has been cited by other articles:
Dalakas, M. C., Rakocevic, G., Schmidt, J., McElroy, B., Harris-Love, M. O., Shrader, J. A., Levy, E. W., Dambrosia, J.
(2009). Reply to: Comment on alemtuzumab and inclusion body myositis. Brain
0: awp276v1-awp276
[Full Text]
Amato, A A, Barohn, R J
(2009). Evaluation and treatment of inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry
80: 1060-1068
[Abstract][Full Text]
Lachenbruch, P. A., Miller, F. W., Rider, L. G.
(2007). Developing international consensus on measures of improvement for patients with myositis. Stat Methods Med Res
16: 51-64
[Abstract]
Lehmann, H. C., Hartung, H.-P., Hetzel, G. R., Stuve, O., Kieseier, B. C.
(2006). Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders.. Arch Neurol
63: 1066-1071
[Abstract][Full Text]
Cordeiro, A C, Isenberg, D A
(2006). Treatment of inflammatory myopathies.. Postgrad. Med. J.
82: 417-424
[Abstract][Full Text]
Griggs, R. C.
(2006). The current status of treatment for inclusion-body myositis. Neurology
66: S30-S32
[Abstract][Full Text]
Tsao, C.-Y., Mendell, J. R., Kissel, J. T.
(2002). Dermatomyositis in Two Siblings and a Brief Review of Familial Dermatomyositis. J Child Neurol
17: 540-542
[Abstract]
Danieli, M G, Malcangi, G, Palmieri, C, Logullo, F, Salvi, A, Piani, M, Danieli, G
(2002). Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis
61: 37-41
[Abstract][Full Text]
Choy, E. H. S., Isenberg, D. A.
(2002). Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford)
41: 7-13
[Abstract][Full Text]
Miller, F. W., Rider, L. G., Chung, Y.-L., Cooper, R., Danko, K., Farewell, V., Lundberg, I., Morrison, C., Oakley, L., Oakley, I., Pilkington, C., Vencovsky, J., Vincent, K., Scott, D. L., Isenberg, D. A.
(2001). Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford)
40: 1262-1273
[Abstract][Full Text]
Lundberg, I., Chung, Y.-L.
(2000). Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology (Oxford)
39: 7-17
[Full Text]
Smith, D. R., Weiner, H. L.
(1997). Immunologic Aspects of Neurologic and Neuromuscular Diseases. JAMA
278: 1956-1961
[Abstract]
Machet, L., Vaillant, L., Gironnet, N., Bouchindhomme, B., Perrotin, D., Lorette, G.
(1997). Failure of Plasmapheresis in the Treatment of Recalcitrant Skin Ulcers in a Patient With Mixed Cryoglobulinemia. Arch Dermatol
133: 389-390
[Abstract]
Chow, R. K. P., Benny, W. B., Coupe, R. L., Dodd, W. A., Ongley, R. C.
(1996). Erythema Elevatum Diutinum Associated With IgA Paraproteinemia Successfully Controlled With Intermittent Plasma Exchange. Arch Dermatol
132: 1360-1364
[Abstract]
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., McCrosky, S.
(1993). A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis. NEJM
329: 1993-2000
[Abstract][Full Text]
Guyatt, G. H., Sackett, D. L., Cook, D. J., the Evidence-Based Medicine Working Group, , Guyatt, G., Bass, E., Brill-Edwards, P., Browman, G., Cook, D., Farkouh, M., Gerstein, H., Haynes, B., Hayward, R., Holbrook, A., Jaeschke, R., Juniper, E., Laupacis, A., Lee, H., Levine, M., Moyer, V., Nishikawa, J., Oxman, A., Patel, A., Philbrick, J., Richardson, W. S., Sauve, S., Sackett, D., Sinclair, J., Trout, K. S., Tugwell, P., Tunis, S., Walter, S., Williams, J. Jr, Wilson, M.
(1993). Users' Guides to the Medical Literature: II. How to Use an Article About Therapy or Prevention A. Are the Results of the Study Valid?. JAMA
270: 2598-2601
[Abstract]
Wallace, D. J.
(1993). Plasmapheresis in Lupus. Lupus
2: 141-143
Previous
